Avara to buy ex Crestor API plant from AstraZeneca
Avara Pharmaceutical Services will buy the UK manufacturing facility at which AstraZeneca made the API for Crestor and Seroquel.
Archives for September 6, 2016
Bioavailability boost: Capsugel to up micronization offering at US site
Capsugel plans to up micronisation capacity at Quakertown, Pennsylvania facility to provide API processing services for clinical candidates and commercial drugs.
AMRI expects to make layoffs during Euticals integration
AMRI has said integrating recent Italian acquisition Prime European Therapeuticals, also known as Euticals, will involve layoffs.
Takeda launches 'first-of-its-kind' global observational study
The open-source study was launched in order to advance understanding of real-world experience with therapies and clinical outcomes in patients with multiple myeloma.
Medidata partners with intelligent analytics firm to improve trial design
Through their strategic commercial partnership, Medidata and SHYFT Analytics are aiming to increase access to healthcare data analytics in clinical trials.
More Cambrex capacity expansion: API firm to grow Karlskoga facility
Cambrex will spend $9m (€8m) to add large-scale manufacturing capability at its API production facility in Karlskoga, Sweden.
IPEC China joins EXCiPACT, promoting excipient safety, quality
The global excipient certification organization has announced IPEC Association (China) Limited as its fifth member, joining IPEC Europe, IPEC Americas, FECC, and PQG (UK).
PPD completes Evidera acquisition, committed to seamless integration
Pharmaceutical Product Development, LLC (PPD), has announced the completed acquisition of Evidera as the two companies commit to making the “seamless offering a reality.”
Cambrex investment continues as industry trends ‘remain favorable’
The latest in a series of investments, Cambrex has recently expanded its Sweden-based site as part of its ongoing investment in small molecule API manufacturing across its global network of facilities.
Allergan bolts on optogenetics platform with RetroSense buy
Allergan has added to its fast-growing eye health portfolio by buying gene therapy firm RetroSense Therapeutics for $60m (€53m) upfront.